The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Regulatory News (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.522
Bid: 1.50
Ask: 1.58
Change: 0.015 (0.98%)
Spread: 0.08 (5.333%)
Open: 1.50
High: 1.536
Low: 1.47
Prev. Close: 1.525
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Placing to Raise £534,375

28 Nov 2023 12:19

RNS Number : 9397U
Hemogenyx Pharmaceuticals PLC
28 November 2023
 

28 November 2023

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014 WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). IN ADDITION, MARKET SOUNDINGS WERE TAKEN IN RESPECT OF THE MATTERS CONTAINED IN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF SUCH INSIDE INFORMATION. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION. 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company") 

Placing to Raise £534,375

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has successfully raised £534,375 (before expenses) through the allotment and issue of 22,500,000 new ordinary shares at 2.375 pence per share (the "Placing", "Placing Shares"). The Placing was oversubscribed and conducted on behalf of the Company by its corporate broker, Peterhouse Capital Limited.

 

The net proceeds from the Placing will be used to facilitate progression of the Company's Chimeric Antigen Receptor ("CAR") T-cells ("HEMO-CAR-T") for the treatment of acute myeloid leukaemia ("AML"). Specifically, and as outlined by the Company in its announcement of 15 November 2023, this fundraise will help the Company to accelerate the completion of work set out in the plan presented and agreed to by the FDA and to re-submit the Investigational New Drug ("IND") application for the HEMO-CAR-T product. The funds will also enable the Company, in view of recently announced successes, to provide modest additional resources to the development of its CBR platform.

 

An application is being made to the London Stock Exchange Main Market and admission of the Placing Shares to trading is expected on or around 4 December 2023 ("Admission"). The Placing Shares will rank pari passu with the existing ordinary shares in the Company.

 

Total Voting Rights

 

For the purpose of the Disclosure Guidance and Transparency Rules, following Admission the enlarged issued share capital of the Company will comprise 1,175,565,988 ordinary shares. The Company does not hold any shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules. 

 

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: 

 

"The markets have at last started to recognise the significant recent progress that the Company has made in the development of both HEMO-CAR-T and CBR platform. Today's Placing will enable the Company to progress with its ambitious schedule to move forward to clinical trials of this exciting potential treatment for AML as well as to further expand the use our CBR platform for the treatment of solid tumours."

 

For the purposes of UK MAR, the person responsible for arranging for the release of this Announcement on behalf of the Company is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder.

Enquiries:

Hemogenyx Pharmaceuticals plc

https://hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

headquarters@hemogenyx.com

Peter Redmond, Director

peter.redmond@hemogenyx.com

SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Adam Cowl

Peterhouse Capital Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

 

The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOELVLFLXFLFFBQ
Date   Source Headline
1st May 20202:06 pmRNSSecond Price Monitoring Extn
1st May 20202:00 pmRNSPrice Monitoring Extension
30th Apr 20204:57 pmRNSFinal Results
30th Apr 20204:40 pmRNSSecond Price Monitoring Extn
30th Apr 20204:36 pmRNSPrice Monitoring Extension
30th Apr 20202:05 pmRNSSecond Price Monitoring Extn
30th Apr 20202:00 pmRNSPrice Monitoring Extension
30th Apr 202011:05 amRNSSecond Price Monitoring Extn
30th Apr 202011:00 amRNSPrice Monitoring Extension
29th Apr 20204:42 pmRNSSecond Price Monitoring Extn
29th Apr 20204:36 pmRNSPrice Monitoring Extension
29th Apr 202011:05 amRNSSecond Price Monitoring Extn
29th Apr 202011:00 amRNSPrice Monitoring Extension
29th Apr 20209:06 amRNSSecond Price Monitoring Extn
29th Apr 20209:00 amRNSPrice Monitoring Extension
28th Apr 20202:06 pmRNSSecond Price Monitoring Extn
28th Apr 20202:00 pmRNSPrice Monitoring Extension
28th Apr 202011:06 amRNSSecond Price Monitoring Extn
28th Apr 202011:00 amRNSPrice Monitoring Extension
27th Apr 20204:41 pmRNSSecond Price Monitoring Extn
27th Apr 20204:36 pmRNSPrice Monitoring Extension
27th Apr 20202:06 pmRNSSecond Price Monitoring Extn
27th Apr 20202:00 pmRNSPrice Monitoring Extension
22nd Apr 20204:40 pmRNSSecond Price Monitoring Extn
22nd Apr 20204:35 pmRNSPrice Monitoring Extension
22nd Apr 20202:05 pmRNSSecond Price Monitoring Extn
22nd Apr 20202:00 pmRNSPrice Monitoring Extension
22nd Apr 202011:00 amRNSCOVID-19 Project Initiated
21st Apr 20202:26 pmRNSApproval and Issuance of European Hu-PHEC Patent
2nd Apr 20202:05 pmRNSSecond Price Monitoring Extn
2nd Apr 20202:00 pmRNSPrice Monitoring Extension
28th Feb 20206:30 pmRNSTotal Voting Rights
20th Feb 20207:00 amRNSHEMO-CAR-T cells Effective Against AML in vivo
20th Feb 20207:00 amRNSHEMO-CAR-T cells Effective Against AML in vivo
11th Feb 20207:00 amRNSApproval and Issuance of U.S. Hu-PHEC Patent
31st Jan 20207:00 amRNSDirector/PDMR Shareholding
30th Jan 20202:05 pmRNSPlacing and Subscription to raise £650,000
15th Jan 202012:30 pmRNSHEMO's CAR-T Cells Effective Against AML in vitro
18th Nov 20197:00 amRNSOperational Update
12th Nov 20197:00 amRNSPresentation at the Investival Showcase
6th Nov 20197:00 amRNSPresentation at the NY Oncology Investor Conf.
23rd Oct 20197:00 amRNSResearch Agreement with Global Pharma Company
21st Oct 20197:00 amRNSPresentation at NY Stem Cell Foundation conference
30th Sep 20197:00 amRNSHalf-year Report
12th Sep 20197:00 amRNSHemogenyx scientific advisor receives Lasker Award
1st Aug 20197:00 amRNSTotal Voting Rights
12th Jul 20197:00 amRNSCDX Patent Application
3rd Jul 20197:00 amRNSDirector/PDMR Shareholding
28th Jun 201912:19 pmRNSResult of AGM
24th Jun 20197:00 amRNSDevelopment of ApbHC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.